



**HOME OF:**  
 Journal of Pediatric Ophthalmology & Strabismus  
 Journal of Refractive Surgery  
 Ocular Surgery News China Edition  
 Ocular Surgery News India Edition  
 Ocular Surgery News Europe/Asia-Pacific Edition

Ocular Surgery News Japan Edition  
 Ocular Surgery News Latin America Edition  
 Ocular Surgery News U.S. Edition  
 Ophthalmic Surgery, Lasers & Imaging

Welcome, Caitlin Log out

- Publications
- Blogs
- News Wire
- Podcasts
- RSS
- Mobile
- Videos
- Classified Marketplace
- CME
- Subscribe

 

OSN SuperSite  Meetings

**MEETINGS & COURSES**

Find a meeting

**FEATURED MEETINGS**

- Hawaiian Eye 2010
- Retina 2010
- Rome 2009
- Kiawah Eye 2009
- OSN New York 2009

**CHOOSE A TOPIC**

- Cataract surgery
- Contact lenses
- Cornea/External disease
- Glaucoma
- Neurosciences
- Oculoplastics
- Ophthalmic business
- Optics
- Pediatrics/Strabismus
- Practice management
- Refractive surgery
- Regulatory/Legislative
- Retina/Vitreous

**BOOKSTORE**

**PODCASTS**

**EDITORIAL BOARDS**

COVER STORIES

EXCLUSIVES

IN THE JOURNALS  
FROM THE PODIUM

**IXTREME INNOVATION**

RETINA RADIO



**OPHTHALMIC BUSINESS**

Posted on the OSN SuperSite April 23, 2009

**iScience Interventional receives \$20.5 million in Series F funding**

MENLO PARK, Calif. — iScience Interventional has secured \$20.5 million in Series F financing from a number of existing and first-time investors, the company announced in a press release.

iScience plans to use these funds to develop therapies for treating glaucoma, age-related macular degeneration and diabetic macular edema. The company's iTTrack canaloplasty microcatheter, which has already received U.S. Food and Drug Administration 510 clearance and a European CE Mark for lowering IOP in patients with open-angle glaucoma, is currently being evaluated in a number of clinical studies in Europe for treating patients with wet AMD who are non-responsive to intravitreal therapy.

The company expects to publish interim results from these studies later this year.

"We believe that these sight specific treatments will represent a dramatic step forward in patient care, while providing a valuable benefit to both private health care providers and public health care systems," Michael F. Nash, president and chief executive officer of iScience, said in the release.

Affinity Capital Management led the round of financing, with Johnson & Johnson Development Corp., L Capital Partners and Clarian Health Ventures participating as first-time investors. Prism VentureWorks, Three Arch Ventures, DeNovo Ventures and Asset Management - all existing investors - also participated in the financing.

Piper Jaffray & Company served as the placement agent for the transaction.

The OSN SuperSite is intended for physician use and all comments will be posted at the discretion of the editors. We reserve the right not to post any comments with unsolicited information about medical devices or other products. At no time will the OSN SuperSite be used for medical advice to patients.

There are no comments for this article. Be the first to comment.

**Your comment**

Name:

Comments:



Type the two words:



**SEE ALSO**

**Alcon CEO, Kevin J. Buehler, looks for 'more shots on goal'**  
 OCULAR SURGERY NEWS U.S. EDITION April 25, 2009

**Alcon posts 2.8% decline in first-quarter sales**  
 Posted on the OSN SuperSite April 23, 2009

**TearLab Osmolarity System receives Medical Design Excellence Award**  
 Posted on the OSN SuperSite April 23, 2009

**MULTIMEDIA**



**Implantable miniature telescope — Clinical results and surgical technique**

Submitted by: David F. Chang, MD (1/21/2008).

**OSN BLOGS**

**JOHN PINTO**  
**Five rules in tough times: Pinto's Development Doctrine**

Although most eye surgeons are hunkering down, waiting out the recession, this is also a time when the most aggressive practice owners and managers are moving ahead with their development plans while everyone else is hiding in their bunkers.